info:eu-repo/semantics/article
EFFECT OF THE USE OF CANNABIDIOL ON THE TREATMENT OF LENNOX-GASTAUT SYNDROME: A SYSTEMATIC REVIEW
Registro en:
10.5902/2236583468765
Autor
Sousa, Davi Santana
da Silva, Jessica Santa Brígida
Silva, Laís Bispo
dos Santos, Yasmin
Junior, Marcos Gabriel do Nascimento
Xavier, Diego Mendes
Aquino, Maria Jane das Virgens
Institución
Resumen
Lennox-Gastaut Syndrome is a common and intractable epileptic encephalopathy. It accounts for about 5% of all childhood epilepsies, causing symptoms such as seizures, behavioral changes and delay in child development. The treatment for this syndrome occurs in a combined way between the physical therapy approach and drug intervention. However, because anticonvulsants have high levels of toxicity and effective incapacity for treatment, new approaches have been analyzed as a proposal for therapeutic intervention, one of them being the use of medicinal plants such as Cannabis sativa. Based on this, this study aims to analyze the effectiveness of cannabidiol in clinical application for patients with Lennox-Gastaut Syndrome, through a systematic literature review. To carry out this study, articles in English, published in the last five years, in the MEDLINE/PubMed, Science Direct, Web of Science, Scopus, BVS/LILACS, SciELO, CAPES Periodicals, CENTRAL and CINAHL Complete databases were recruited from of the descriptors Cannabidiol and Lennox-Gastaut Syndrome, combined by the Boolean AND operator. The review research was registered in PROSPERO with the code CRD42021229584 and followed the criteria of the PICO strategy. From the analysis and careful investigation of the results of the databases, two articles were included in the study, selected from the screening of 503 studies. The discussion of the articles was carried out using criteria that define the pharmacological parameters, the side effects of cannabidiol and the effects on the individuals' quality of life. Therefore, the study demonstrated that cannabidiol is effective in the clinical condition of patients with Lennox-Gastaut Syndrome, but further studies are needed to more selectively investigate toxicity, ideal dosage, product validity, as well as possible drug interactions and side effects.